ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA). Validation of the application enables the evaluation process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) to begin.
Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.
Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTA®in a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in China.
Pablo Graiver, founder and former CEO of Antidote, has joined Drumroll Health as its new Chief Executive Officer. The company also announced that industry veterans Paul Bleicher and Ritesh Patel have joined the Advisory Board, alongside Craig Lipset and Jennifer Levin Carter.
In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations
Intelinair has raised $20 million in Series B funding to continue to scale the company and its flagship crop intelligence platform, AGMRI®.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA®, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma (DLBCL).
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).
LiquiGlide, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced the launch of zero-waste packaging for the health and beauty industry.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
Transparency Life Sciences, a digital health startup that develops technology solutions to foster closer partnerships between patients and health professionals, today unveiled a new corporate identity and company name: Drumroll Health.
The U.K.-based startup is clearly making waves amongst investors. It has now raised yet another seed funding round, this time totalling $2.5 million, from 65 health-tech and consumer-tech investors, taking its total raised to $5 million.
Cibus, a leader in precision gene editing in agriculture, and GDM, a leading global soybean research company, today announced a strategic collaboration focused on developing and delivering new solutions for challenges faced by soybean farmers.
FibroGen, Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
LiquiGlide, the inventors of a breakthrough technology that's revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced that the U.S. Food and Drug Administration (FDA) has accepted a Device Master File (MAF) from LiquiGlide's biomedical division for its novel, patented coating platform.
Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas.
SAN DIEGO – May 4, 2021 – Cibus, a leader in precision gene editing and trait development in agriculture, welcomes the published findings of the European Commission’s New Genomics Techniques (NGTs) study.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.
The company's $13.5M round and additional partnerships with Colgate, the Mibelle Group and Yves Béhar prove technology's ability to create market-viable solutions for no-waste products, packaging, and manufacturing processes.